Purple Coneflower (<i>Echinacea</i>) – Properties, Medicines, for Children

Echinacea, commonly referred to as purple coneflower, is a medicinal herb indigenous to North America that has since been cultivated across Europe and parts of Asia. Botanically classified within the *Asteraceae* family and the *Astrales* order, this plant is also colloquially known as "American coneflower" or "hedgehog plant," though its primary medicinal applications focus on three distinct species: *Echinacea purpurea* (purple coneflower), *Echinacea angustifolia* (narrow-leaf coneflower), and *Echinacea pallida* (pale coneflower). Morphologically, these perennial herbs typically reach heights of approximately one meter, featuring ovate-lanceolate leaves with distinctly serrated margins. The inflorescence consists of composite flower heads comprising tubular disc florets at the center and ray florets along the periphery. The plant’s versatility extends to multiple domains: it serves as a raw material for pharmaceutical drugs and dietary supplements, functions as an ornamental garden plant, acts as a nectar source for pollinators, and is even incorporated into animal feed formulations. Therapeutically, the most commonly utilized preparations include alcoholic, oil-based, or aqueous extracts derived from the root and aerial parts of the plant. The sustained and growing incorporation of Echinacea extracts into contemporary herbal remedies and supplements stems from its well-documented health-promoting properties, which have solidified its status as a staple ingredient in modern botanical medicine [1].

Purple coneflower (Echinacea) is exceptionally rich in diverse bioactive compounds, including chlorogenic acid and its isomers, flavonoids (quercetin, rutoside, apigenin), essential oils, immunologically active polysaccharides, and trace pyrrolizidine alkaloids. The root additionally contains the characteristic phenolic glycoside echinacoside, alongside inulin and betaine. Pharmacologically, Echinacea functions primarily as a nonspecific immunostimulant. Its high-molecular-weight polysaccharides and alkamides stimulate granulocyte and monocyte activity, enhancing the phagocytic capacity of macrophages and promoting the release of protective cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukins (IL-1, IL-6, IL-10). Furthermore, caffeic acid derivatives exert noticeable antioxidant and antiviral effects, particularly against respiratory syncytial and influenza viruses. However, due to its potent immune-activating properties, Echinacea is strictly contraindicated in individuals with progressive systemic and autoimmune disorders, such as multiple sclerosis (MS), systemic lupus erythematosus, rheumatoid arthritis, active tuberculosis, leukemia, and other myeloproliferative disorders. Immune stimulation in these conditions risks exacerbating autoimmune tissue damage or interfering with immunosuppressive medications. Additionally, preparations containing Echinacea should not be administered to patients with HIV/AIDS, pregnant or breastfeeding women, or children under 12 years of age without explicit medical supervision.

For centuries, traditional herbal medicine has employed a variety of preparations derived from purple coneflower (Echinacea purpurea), including ethanol-based tinctures, aqueous macerates, freshly pressed plant juices, topical ointments, and water infusions made from the aerial parts or root of the plant. However, contemporary pharmaceutical advancements have significantly expanded these options, now offering patients a range of optimized, user-friendly Echinacea-based formulations. These include sustained-release tablets, gelatin capsules containing micronized powder, oral liquid drops, palatable syrups, as well as semi-solid ointments and gels designed for cutaneous and mucosal application. Liquid preparations typically rely on a standardized glycerin-ethanol extract obtained from high-quality botanical raw material, whereas solid dosage forms—such as tablets or capsules—are formulated using freeze-dried, powdered herb or root of Echinacea. It is crucial to emphasize that therapy with Echinacea preparations demands consistent and prolonged use, as the initial observable therapeutic benefits generally manifest only after a minimum of three to four weeks of regular administration. In accordance with expert recommendations, a two-week interruption in supplementation is advised following a four-week treatment cycle to mitigate the potential development of organismal tolerance to the plant’s bioactive compounds [1].

Dietary supplements and medicinal formulations derived from purple coneflower (*Echinacea purpurea*) are approved for use in adolescents who have reached their 12th year of age; however, a substantial proportion of commercially available products—particularly standardized tablets or capsules with fixed bioactive compound concentrations—are explicitly contraindicated for individuals under 18 years old. In exceptional circumstances, following consultation with a pediatric specialist, a modified, reduced dosage may be considered for children aged 6 to 12 years, but solely during periods of heightened susceptibility to infections or amid active viral/bacterial infectious episodes. The plant demonstrates well-documented immunomodulatory, anti-inflammatory, and antioxidant properties, rendering it a valuable adjunctive therapy for respiratory tract disorders—including rhinitis, bronchitis, and pharyngitis—as well as urinary tract infections. Nevertheless, caution must be exercised: due to potential interactions with immunosuppressive medications (e.g., glucocorticoids, cytostatics) and the risk of paradoxical immune suppression with prolonged administration, Echinacea-based preparations are strictly contraindicated in patients diagnosed with leukemia, HIV/AIDS, or those undergoing immunosuppressive therapy. Routine prophylactic or long-term use without clear clinical justification is strongly discouraged.